ChinaDaily Briefs

Daily Brief China: JD.com , Horizon Robotics, S.F. Holding, T.S. Lines, JNBY Design Ltd, SGX Rubber Future TSR20, Corn Active Contract, China Shineway Pharmaceutical and more

In today’s briefing:

  • Hang Seng Internet & IT Index (HSIII) Rebalance Preview: Capping Flows in December
  • Horizon Robotics (9660 HK) IPO: Valuation Insights
  • SF Holding Pre-IPO: Proposed Interim & Special Dividends of 1.40 CNY Per Share Ahead of HK Listing
  • T.S. Lines Pre-IPO – PHIP Updates – Shipping Volumes Improved, However Paid Another Large Dividend
  • JD.com (9618-HK): Positive Technical Analysis Signals
  • JNBY (3306 HK): >34% ROCE Track Record/10% Dividend Yield/Net Cash Business
  • Helixtap China Report: Declining Inventory Point At Improved Demand; Sustainability Questionable
  • China’s Corn Under Extreme Weather Threat // Bad News Again for Orange Production
  • China Shineway Pharmaceutical (2877.HK) – Performance Would Pick up in 24H2


Hang Seng Internet & IT Index (HSIII) Rebalance Preview: Capping Flows in December

By Brian Freitas

  • The December rebalance for the HSIII Index only involves capping to limit stocks to 12% of the index weight. There will not be any constituent changes.
  • Estimated one-way turnover at the rebalance is 4.4% resulting in a round-trip trade of HK$2.9bn (US$378m).
  • The largest outflows are expected to be from Meituan (3690 HK) and JD.com (9618 HK) with inflows spread across the other index constituents.

Horizon Robotics (9660 HK) IPO: Valuation Insights

By Arun George


SF Holding Pre-IPO: Proposed Interim & Special Dividends of 1.40 CNY Per Share Ahead of HK Listing

By Daniel Hellberg

  • SF Holding proposes interim & special dividends for owners of A-shares
  • Combined cash dividend totals 1.40 CNY per share, yielding about 3.3%
  • Meeting October 29 to approve dividends, Q3 results, planned HK listing

T.S. Lines Pre-IPO – PHIP Updates – Shipping Volumes Improved, However Paid Another Large Dividend

By Clarence Chu

  • T.S. Lines (TSL HK) is looking to raise at least US$100m in its upcoming Hong Kong IPO.
  • T.S. Lines (TSL) is a container shipping firm primarily operating in the Asia Pacific (APAC) region.
  • In a previous note, we looked at the firm’s past performance. In this note, we talk about the recent updates from its filings.

JD.com (9618-HK): Positive Technical Analysis Signals

By Wium Malan, CFA

  • Despite a share price correction this month, JD.com (9618 HK) remains firmly amid an earnings upgrade cycle driven by improved profitability expectations.
  • Following significant share price volatility over the past 2 months, JD.com’s near-term momentum indicators currently display bullish signals.
  • JD.com still trades at more than one standard deviation below its 5-year historic average forward PE ratio, and near the lowest level it has ever been.

JNBY (3306 HK): >34% ROCE Track Record/10% Dividend Yield/Net Cash Business

By Sameer Taneja


Helixtap China Report: Declining Inventory Point At Improved Demand; Sustainability Questionable

By Arusha Das

  • Inventory lowest since February 2024
  • Arbitrage widens for African and Indonesian rubber
  • Expansion in imports & exports in August

China’s Corn Under Extreme Weather Threat // Bad News Again for Orange Production

By The Commodity Report

  • China’s Corn Under Extreme Weather Threat China’s corn production is currently under pressure due to extreme weather events in the country.
  • Still, as it seems this might not be enough to even lift prices up a little bit. Local prices have ticked higher since the end of September, but they’re still close to four-year lows.
  • Stockpiles of corn are plentiful, and demand is currently sluggish as the second-largest economy of the world battles its own economy demons at the moment.

China Shineway Pharmaceutical (2877.HK) – Performance Would Pick up in 24H2

By Xinyao (Criss) Wang

  • Shineway’s revenue experienced negative growth in 24H1 as expected, but net profit performance beat expectations (up 27.5% YoY). However, if excluding those one-time gains, net profit was down 14% YoY.
  • In 24H2, Shineway’s performance is expected to pick up, and YoY revenue growth 2024 full-year would return to positive (e.g. 5-10% YoY). The only concern is TCM formula granule VBP.
  • China Shineway Pharmaceutical (2877 HK)’s overall financial position is healthy.  However, even with large cash balance, the current dividend is not satisfactory, which has more room to improve.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars